355 related articles for article (PubMed ID: 23456262)
1. Molecular pathogenesis of multiple myeloma: basic and clinical updates.
Chesi M; Bergsagel PL
Int J Hematol; 2013 Mar; 97(3):313-23. PubMed ID: 23456262
[TBL] [Abstract][Full Text] [Related]
2. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Mulligan G; Lichter DI; Di Bacco A; Blakemore SJ; Berger A; Koenig E; Bernard H; Trepicchio W; Li B; Neuwirth R; Chattopadhyay N; Bolen JB; Dorner AJ; van de Velde H; Ricci D; Jagannath S; Berenson JR; Richardson PG; Stadtmauer EA; Orlowski RZ; Lonial S; Anderson KC; Sonneveld P; San Miguel JF; Esseltine DL; Schu M
Blood; 2014 Jan; 123(5):632-9. PubMed ID: 24335104
[TBL] [Abstract][Full Text] [Related]
3. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.
Chng WJ; Huang GF; Chung TH; Ng SB; Gonzalez-Paz N; Troska-Price T; Mulligan G; Chesi M; Bergsagel PL; Fonseca R
Leukemia; 2011 Jun; 25(6):1026-35. PubMed ID: 21468039
[TBL] [Abstract][Full Text] [Related]
5. Advances in the pathogenesis and diagnosis of multiple myeloma.
Chesi M; Bergsagel PL
Int J Lab Hematol; 2015 May; 37 Suppl 1():108-14. PubMed ID: 25976968
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Avet-Loiseau H; Leleu X; Roussel M; Moreau P; Guerin-Charbonnel C; Caillot D; Marit G; Benboubker L; Voillat L; Mathiot C; Kolb B; Macro M; Campion L; Wetterwald M; Stoppa AM; Hulin C; Facon T; Attal M; Minvielle S; Harousseau JL
J Clin Oncol; 2010 Oct; 28(30):4630-4. PubMed ID: 20644101
[TBL] [Abstract][Full Text] [Related]
7. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
[TBL] [Abstract][Full Text] [Related]
9. Genomic stratification of multiple myeloma treated with novel agents.
Jiang A; Reece D; Chang H
Leuk Lymphoma; 2012 Feb; 53(2):202-7. PubMed ID: 21823830
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
[TBL] [Abstract][Full Text] [Related]
11. Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events.
Chng WJ; Mulligan G; Bryant B; Bergsagel L
Blood; 2007 Apr; 109(8):3610-1. PubMed ID: 17409348
[No Abstract] [Full Text] [Related]
12. Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients.
Levacque Z; Rosales JL; Lee KY
Cell Cycle; 2012 Nov; 11(21):4093-5. PubMed ID: 22987154
[No Abstract] [Full Text] [Related]
13. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D; Keats JJ; Lonial S; Vertino PM; Boise LH
Nat Commun; 2019 Apr; 10(1):1911. PubMed ID: 31015454
[TBL] [Abstract][Full Text] [Related]
14. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.
Stessman HA; Mansoor A; Zhan F; Janz S; Linden MA; Baughn LB; Van Ness B
Leukemia; 2013 Oct; 27(10):2075-7. PubMed ID: 23728080
[No Abstract] [Full Text] [Related]
15. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
Chang H; Trieu Y; Qi X; Jiang NN; Xu W; Reece D
Leuk Res; 2011 Jan; 35(1):95-8. PubMed ID: 20537706
[TBL] [Abstract][Full Text] [Related]
16. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.
Weinhold N; Kirn D; Seckinger A; Hielscher T; Granzow M; Bertsch U; Egerer G; Salwender H; Blau IW; Weisel K; Hillengass J; Raab MS; Hose D; Goldschmidt H; Jauch A
Haematologica; 2016 Mar; 101(3):e116-9. PubMed ID: 26611471
[No Abstract] [Full Text] [Related]
17. Molecular pathogenesis and a consequent classification of multiple myeloma.
Bergsagel PL; Kuehl WM
J Clin Oncol; 2005 Sep; 23(26):6333-8. PubMed ID: 16155016
[TBL] [Abstract][Full Text] [Related]
18. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M; Kobayashi T; Fuchida S; Yamamoto-Sugitani M; Ohshiro M; Shimura Y; Mizutani S; Nagoshi H; Sasaki N; Nakayama R; Chinen Y; Sakamoto N; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Kuroda J; Taniwaki M
Int J Hematol; 2012 May; 95(5):516-26. PubMed ID: 22426624
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Bergsagel PL; Kuehl WM; Zhan F; Sawyer J; Barlogie B; Shaughnessy J
Blood; 2005 Jul; 106(1):296-303. PubMed ID: 15755896
[TBL] [Abstract][Full Text] [Related]
20. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Neben K; Lokhorst HM; Jauch A; Bertsch U; Hielscher T; van der Holt B; Salwender H; Blau IW; Weisel K; Pfreundschuh M; Scheid C; Dührsen U; Lindemann W; Schmidt-Wolf IG; Peter N; Teschendorf C; Martin H; Haenel M; Derigs HG; Raab MS; Ho AD; van de Velde H; Hose D; Sonneveld P; Goldschmidt H
Blood; 2012 Jan; 119(4):940-8. PubMed ID: 22160383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
